British Patient Capital commits $65m to SV Health Investors, to invest in life-changing biotechnology companies
SV Health Investors hits $265m final close for first dedicated biotech fundraiseRead More
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2Fevidation-wordmark-black-cmyk.png)
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2FSV-website-news.jpg)
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2Fhealthify-logo.png){kind=logo}
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Fkate-binghama-banner.jpg)
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2Fribometrix.png)
4 August 2020Portfolio NewsRibometrix Further Expands Leadership with Appointment of Barclay "Buck" Phillips as Chief Operating Officer and Chief Financial Officer
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FCatabasis-logo.png)
4 August 2020Portfolio NewsCatabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FXilio-logo.png)
23 July 2020Portfolio NewsXilio Therapeutics Appoints Paul J. Clancy to its Board of Directors- 20 July 2020SV NewsBritish Patient Capital commits $65m to SV Health Investors, to invest in life-changing biotechnology companies
- 6 July 2020Portfolio NewsAVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FPionyr-Logo.png)
23 June 2020Portfolio NewsSV Health Investors notes Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics- 23 June 2020Portfolio NewsBicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FAlchemab-logo.png)
23 June 2020Portfolio NewsAlchemab Therapeutics among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK- 22 June 2020Portfolio NewsDeciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
- 17 June 2020Portfolio NewsXilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FX4-Pharmaceuticals.png)
11 June 2020Portfolio NewsX4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer- 8 June 2020Portfolio NewsDeciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology